Policy & Regulation
Regeneron Pharmaceuticals signs research collaboration and option licensing agreement with Vyriad
8 November 2019 -

Regeneron Pharmaceuticals (NASDAQ: REGN), a biotechnology company, has signed a research collaboration and option licencing agreement with United States-based Vyriad, it was reported yesterday.

The contract has been signed to discover and develop new oncolytic virus-based treatments for treating various forms of cancer.

The companies will also sign a five year research contract to use Regeneron's VelociSuite technologies to design and test Vesicular Stomatitis Virus-based oncolytic virus treatments. The firms will commence a phase two clinical study in 2020 to evaluate Regeneron's PD-1 inhibitor Libtayo (cemiplimab-rwlc) in combination with Vyriad's oncolytic virus Voyager-V1 in multiple types of cancer. Under the terms of the deal, Vyriad will secure an upfront payment, while Regeneron will make an equity investment in the company.

Login
Username:

Password:


Related Headlines

BioMarin Pharmaceutical files BLA with US FDA for valoctocogene roxaparvovec for treating adults with haemophilia A

SGI-DNA Equipping Researchers with Tools to Combat Coronavirus Disease

US Merck Receives Complete Response Letter from the US FDA for Supplemental Biologics License Applications for Keytruda Six-Week Dosing Schedule

FDA Grants Priority Review to Genentech's Tecentriq Monotherapy as First-line Treatment of Certain People with Advanced Non-small Cell Lung Cancer

Cellectis and Servier Expand Collaboration on UCART19 Products

Ascelia Pharma AB reports first patient enrolled in pivotal phase III clinical study SPARKLE with lead candidate Mangoral

Humanetics acquires API manufacturing assets of new drug candidate BIO 300

ICON concludes acquisition of MedPass International

Updated CheckMate -025 Results Show 26% of Patients Treated with Opdivo are Alive at Five Years in Patients with Previously Treated Advanced or Metastatic Renal Cell Carcinoma

Opdivo Plus Yervoy Demonstrates Continued Survival Benefit at 42-Month Follow-up in Patients with Previously Untreated Advanced or Metastatic Renal Cell Carcinoma

Neuropore Therapies Receives USD 500,000 Grant from The ALS Association to Explore ALS Treatments that Inhibit Neuronal Damage from Disease-Related Inflammation

Isofol Medical AB begins treatment of first patient in Japan under Phase 3 AGENT Study of arfolitixorin

AVROBIO raises USD100m from public offering

Sanofi Pasteur to reveal path forward for COVID-19 vaccine development

Navidea Biopharmaceuticals Gains USD 7.6m in Additional Funding